ASCO: Novartis To Face Challengers In Growing Radiopharmaceutical Space Scrip Pharma Intelligence 2d Pharma
Positive Del-brax biomarker data offers early support for Novartis’s Avidity bet Scrip Pharma Intelligence 2d Pharma
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 Novartis (Press Release) 6d
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases Novartis (Press Release) 06:30 Mon, 01 Jun
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) Novartis (Press Release) 1d
India needs to remain attractive for innovation-led investment: Judith Love, Novartis The Times of India 2d
